Details of the Drug-Related molecule(s) Interaction Atlas

Tricyclic heterocycle derivative 4 Drug Info

PMID26077642-Compound-Figure3D

Cross-matching ID

PubChem CID

56644389

TTD Drug ID

DM9XBL4

General Information of Drug (ID: DM9XBL4)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Patented Agent(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Ubiquitin carboxyl-terminal hydrolase 14 (USP14)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID26077642-Compound-Figure3A	DMENX90	N. A.	N. A.	Patented	[1]
BAP-15	DMOW07D	Solid tumour/cancer	2A00-2F9Z	Preclinical	[2]
IU1	DMJ0A2R	Neurodegenerative disorder	8A20-8A23	Preclinical	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ubiquitin carboxyl-terminal hydrolase 14 (USP14)	TTVSYP9	UBP14_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208.
2	The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer. Oncotarget. 2019 Oct 15;10(57):5932-5948.
3	Neurotoxic mechanisms by which the USP14 inhibitor IU1 depletes ubiquitinated proteins and Tau in rat cerebral cortical neurons: Relevance to Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis. 2017 Jun;1863(6):1157-1170.